Ivosidenib · Tibsovo

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
JP
  • IDH1 mutation-positive unresectable biliary tract cancer that has progressed after cancer chemotherapy (Tibsovo tablets 250 mg; Nihon Servier K.K.)PMDA
  • IDH1 gene mutation-positive acute myeloid leukaemia (Tibsovo tablets 250 mg; Nihon Servier K.K.). PMDA lists the entry dated 2025-03-27 (review report date); a later entry (2026-06-19) concerns biliary tract cancer.PMDA
Product first approved 2025
EU
  • With azacitidine for newly diagnosed IDH1 R132-mutated AML not eligible for standard induction chemotherapy; monotherapy for locally advanced or metastatic IDH1 R132-mutated cholangiocarcinoma. Holder: Les Laboratoires Servier.
Product first approved 2023EMA
CN
  • Adults with relapsed/refractory AML with a susceptible IDH1 mutation (approved on CStone's NDA; Greater China rights later moved to Servier)
Product first approved 20221stoncology.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Acute Myeloid Leukemia
NCT03839771 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2019-03-01 – 2034-09-19 · Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
What this study did
Other / comorbidity
NCT07745296 · UNICANCER
2027-01-02 – 2033-07-02 · Biliary Tract Cancer (BTC)
What this study did
NCT06127407 · Servier Bio-Innovation LLC
2024-07-09 – 2030-11-26 · Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
What this study did
NCT06465953 · Institut de Recherches Internationales Servier
2024-12-03 – 2028-12-01 · Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
What this study did
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT05876754 · Servier Affaires Médicales
2023-05-03 – 2027-12-01 · Cholangiocarcinoma
What this study did
Phase 2/3 (1)
Acute Myeloid Leukemia
NCT03013998 · Beat AML, LLC
2016-11 – 2032-12 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
What this study did
Phase 2 (22)
Acute Myeloid Leukemia
NCT06707493 · Massachusetts General Hospital
2026-01-16 – 2030-01-01 · IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
What this study did
NCT07507760 · PETHEMA Foundation
2026-06-12 – 2029-04 · Acute Myeloid Leukemia With Gene Mutations
What this study did
NCT07548710 · Ruijin Hospital
2026-05-01 – 2028-12-21 · Acute Myeloid Leukemia
What this study did
NCT07937124 · First Affiliated Hospital of Zhejiang University
2026-12-15 – 2028-12-14 · Acute Myeloid Leukemia
What this study did
NCT04493164 · M.D. Anderson Cancer Center
2020-12-30 – 2028-06-01 · Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT07392242 · Memorial Sloan Kettering Cancer Center
2026-01-27 – 2028-01 · Acute Myeloid Leukemia
What this study did
NCT07607418 · Ruijin Hospital
2026-05-22 – 2027-12-30 · AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
What this study did
NCT03503409 · Groupe Francophone des Myelodysplasies
2019-05-14 – 2027-04-02 · Myelodysplastic Syndromes, Acute Myeloid Leukemia
What this study did
NCT07007949 · The First Affiliated Hospital of Soochow University
2025-06-01 – 2026-12-31 · Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib
What this study did
NCT04044209 · Yale University
2020-02-12 – 2023-09 · Myelodysplastic Syndromes, Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07260175 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-11-18 – 2031-12 · Cholangiocarcinoma, IDH Mutation
What this study did
NCT05030441 · Washington University School of Medicine
2022-04-01 – 2030-01-31 · Clonal Cytopenia of Undetermined Significance
What this study did
NCT04195555 · National Cancer Institute (NCI)
2020-07-20 – 2027-05-09 · Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
What this study did
NCT06081829 · Servier
2023-10-10 – 2027-05 · Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
What this study did
NCT04278781 · Memorial Sloan Kettering Cancer Center
2020-03-04 – 2027-03 · Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation
What this study did
NCT03155620 · National Cancer Institute (NCI)
2017-07-31 – 2027-01-06 · Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
What this study did
NCT07282262 · Peking Union Medical College Hospital
2024-05-01 – 2026-10-01 · Biliary Tract Cancer
What this study did
NCT04056910 · Jason J. Luke, MD
2021-09-20 – 2023-11-13 · Advanced Solid Tumor, IDH1 Mutation, Glioma
What this study did
Phase 1/2 (6)
Acute Myeloid Leukemia
NCT06611839 · Institute of Hematology & Blood Diseases Hospital, China
2025-10-17 – 2028-10-01 · AML, IDH1 Mutation, Treatment
What this study did
NCT04774393 · M.D. Anderson Cancer Center
2021-05-24 – 2027-11-29 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03471260 · M.D. Anderson Cancer Center
2018-03-19 – 2027-09-30 · Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT06501625 · Institut de Recherches Internationales Servier
2024-12-16 – 2027-09-13 · Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
What this study did
NCT05921760 · Servier Bio-Innovation LLC
2023-10-23 – 2024-11-21 · IDH1-mutant Cholangiocarcinoma
What this study did
Phase 1 (20)
Acute Myeloid Leukemia
NCT05756777 · Memorial Sloan Kettering Cancer Center
2023-10-25 – 2027-04-21 · Acute Myeloid Leukemia (AML)
What this study did
NCT05010772 · M.D. Anderson Cancer Center
2021-10-25 – 2026-12-31 · Acute Myeloid Leukemia
What this study did
NCT02632708 · Institut de Recherches Internationales Servier
2015-12-31 – 2026-07-24 · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
What this study did
NCT04655391 · City of Hope Medical Center
2022-06-25 – 2023-12-15 · Recurrent Acute Myeloid Leukemia
What this study did
NCT04176393 · CStone Pharmaceuticals
2019-11-12 – 2023-01-18 · Relapsed or Refractory Acute Myeloid Leukemia
What this study did
NCT04250051 · Northwestern University
2020-12-21 – 2022-12-20 · Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Newly Diagnosed Acute Myeloid Leukemia (AML), IDH1 Mutation Myeloid Neoplasms, Acute Myeloid Leukemia (AML)
What this study did
Other / comorbidity
NCT06291987 · University of Chicago
2024-09-19 – 2029-05 · Myeloproliferative Neoplasms
What this study did
NCT07006688 · Servier Bio-Innovation LLC
2026-01-14 – 2028-08-31 · IDH1-Mutated Malignancies
What this study did
NCT05209074 · Case Comprehensive Cancer Center
2022-09-08 – 2026-12-31 · Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
What this study did
NCT03343197 · Institut de Recherches Internationales Servier
2018-03-20 – 2025-03-28 · Glioma
What this study did
NCT02073994 · Institut de Recherches Internationales Servier
2014-03-01 – 2024-01-04 · Cholangiocarcinoma, Chondrosarcoma, Glioma, Other Advanced Solid Tumors
What this study did
NCT04088188 · Academic and Community Cancer Research United
2021-01-25 – 2023-12-01 · Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma
What this study did
NCT04955938 · University of Chicago
2021-10-29 – 2023-06-07 · IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
What this study did
NCT03564821 · Massachusetts General Hospital
2019-01-16 – 2023-06-06 · IDH1 Mutation Myeloid Neoplasms
What this study did
NCT03282513 · Agios Pharmaceuticals, Inc.
Run by former owner AGIOS PHARMACEUTICALS, INC.
2017-09-26 – 2018-03-31 · Hepatic Impairment
What this study did
NCT03071770 · Agios Pharmaceuticals, Inc.
Run by former owner AGIOS PHARMACEUTICALS, INC.
2017-03-31 – 2017-09-06 · Healthy
What this study did
NCT02831972 · Agios Pharmaceuticals, Inc.
Run by former owner AGIOS PHARMACEUTICALS, INC.
2016-06 – 2016-10 · Healthy
What this study did
NCT02579707 · Agios Pharmaceuticals, Inc.
Run by former owner AGIOS PHARMACEUTICALS, INC.
2015-10 – 2016-06 · Healthy
What this study did
NCT02489513 · Agios Pharmaceuticals, Inc.
Run by former owner AGIOS PHARMACEUTICALS, INC.
2015-06 – 2015-10 · Healthy Volunteers
What this study did
Early phase / not applicable (3)
Acute Myeloid Leukemia
NCT07131059 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-11 – 2028-10-30 · AML, Adult
What this study did
NCT06265545 · Institute of Hematology & Blood Diseases Hospital, China
2024-02-22 – 2028-06-30 · AML, Refractory, Relapsed
What this study did
Other / comorbidity
NCT06648473 · Duke University
2026-01-01 – 2027-12-01 · Low Grade Glioma of Brain
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ivosidenib (Tibsovo): this drugApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
Safusidenib
Phase 3(overall)
Small moleculeMutant IDH1
not yet graded(overall)
No reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 69 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(32 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tibsovo (Ivosidenib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT02074839 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT05010772 · CT.gov ↗
What to watch
2027 (14)
March 2027 (1)
Phase 2Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene MutationActive not recruiting
Est. primary completion 2027-03 · NCT04278781 · CT.gov ↗
What to watch
April 2027 (3)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-02 · NCT03503409 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-17 · NCT03839771 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-21 · NCT05756777 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-30 · NCT07607418 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1/2Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationActive not recruiting
Est. primary completion 2027-09-13 · NCT06501625 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT03471260 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT05401097 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-15 · NCT05907057 · CT.gov ↗
What to watch
November 2027 (2)
Phase 3Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)Recruiting
Est. primary completion 2027-11-01 · NCT06465953 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-29 · NCT04774393 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3CholangiocarcinomaActive not recruiting
Est. primary completion 2027-12-01 · NCT05876754 · CT.gov ↗
What to watch
2028 (8)
January 2028 (3)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01 · NCT07392242 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-01 · NCT06707493 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-30 · NCT06265545 · CT.gov ↗
What to watch
February 2028 (1)
Phase 3Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation …Recruiting
Est. primary completion 2028-02-01 · NCT06127407 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06-01 · NCT04493164 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1IDH1-Mutated MalignanciesRecruiting
Est. primary completion 2028-07-31 · NCT07006688 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-12-14 · NCT07937124 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-04 · NCT07507760 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1Myeloproliferative NeoplasmsRecruiting
Est. primary completion 2029-05 · NCT06291987 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-10-01 · NCT06717958 · CT.gov ↗
What to watch
2030 (3)
January 2030 (1)
Phase 2Clonal Cytopenia of Undetermined SignificanceActive not recruiting
Est. primary completion 2030-01-31 · NCT05030441 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT07463768 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Cholangiocarcinoma, IDH MutationRecruiting
Est. primary completion 2030-12 · NCT07260175 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-12 · NCT03013998 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
Phase 3Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2033-07-02 · NCT07745296 · CT.gov ↗
What to watch

See the full readout calendar ↗